Advertisement

Current Anesthesiology Reports

, Volume 8, Issue 4, pp 362–367 | Cite as

New Cancer Therapies: Implications for the Perioperative Period

  • Tayab Andrabi
  • Katy E. French
  • Muzaffar H. Qazilbash
Cancer Anesthesia (B Riedel and V Gottumukkala, Section Editors)
  • 11 Downloads
Part of the following topical collections:
  1. Cancer Anesthesia

Abstract

Purpose of Review

Cancer is on the rise. Standing on verge of exciting discoveries, research is being translated into therapies that are being widely administered to patients. Providing a hope for cure, where none existed before. This new body of knowledge has come from a better understanding of cancer genetics, molecular and sub molecular behavior, and understanding of cancer-generated cellular environments. These have led to development of immunotherapy and its many sub-genres, improvement and introduction of new radiation technologies, and decreasing toxicities of existing chemotherapies.

Recent Findings

The purpose of this review is to have a summary look at this huge landscape of cancer therapy. Specially looking at toxicities that an anesthesiologist should be familiar with while providing perioperative care for these patients, complications like tumor lysis syndrome, cytokine release syndromes, Kounis syndrome, myocarditis, encephalopathies, and pituitary failure need to be kept in mind.

Summary

One should be knowledgeable about these therapies and approach these patients with a high index of suspicion. Anesthesiologists will need to refine preoperative assessment with appropriate testing and intraoperative and postoperative management in collaboration with oncologists, while involving the expertise of internists, cardiologist, and endocrinologists in helping assess and manage these patients in the perioperative period.

Keywords

Anesthesia assessment in cancer patients Perioperative implications of cancer therapy New cancer therapies, side effects, and management in perioperative period Immunotherapy, mechanism of actions, and side effects Side effects 

Notes

Compliance with Ethical Standards

Conflict of Interest

TayabAndrabi, Katy E. French, and Muzaffar H. Qazilbash declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Huitink JM, Teoh WH. Current cancer therapies - a guide for perioperative physicians. Best Pract Res Clin Anaesthesiol. 2013;27(4):481–92.CrossRefPubMedGoogle Scholar
  2. 2.
    Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120(2):617–24.CrossRefPubMedGoogle Scholar
  3. 3.
    •• Aakre BM, Efem RI, Wilson GA, Kor DJ, Eisenach JH. Postoperative acute respiratory distress syndrome in patients with previous exposure to bleomycin. Mayo Clin Proc. 2014;89(2):181–9 Risk of postoperative ARDS in patients exposed to systemicbleomycin appears to be lower than expected. Smoking status may be an important factor that modifies the risk of postoperative ARDS. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Goldiner PL, Carlon GC, Cvitkovic E, Schweizer O, Howland WS. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J. 1978;1(6128):1664–7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gudaityte J, Dvylys D, Simeliunaite I. Anaesthetic challenges in cancer patients: current therapies and pain management. Acta Med Austriaca. 2017;24(2):121–7.Google Scholar
  6. 6.
    Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Bilginoglu A, Aydin D, Ozsoy S, Aygun H. Protective effect of melatonin on adriamycin-induced cardiotoxicity in rats. Turk Kardiyoloji Dernegi arsivi: Turk Kardiyoloji Derneginin yayin organidir. 2014;42(3):265–73.CrossRefGoogle Scholar
  8. 8.
    • Sahai SK. Perioperative assessment of the cancer patient. Best Pract Res Clin Anaesthesiol. 2013;27(4):465–80 This article reviews the perioperative concerns that are specific to thepatient with cancer. CrossRefPubMedGoogle Scholar
  9. 9.
    Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592–600.CrossRefPubMedGoogle Scholar
  10. 10.
    Zou L-Q, Zhang B-L, Chang Q, Zhu FP, Li YY, Wei YQ, et al. 3D conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol: WJG. 2014;20(45):17227–34.CrossRefPubMedGoogle Scholar
  11. 11.
    Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Physics. 2012;84(1):125–9.CrossRefGoogle Scholar
  12. 12.
    Fu J, Willner M, Chen L, Tan R, Achterhold K, Bech M, et al. Helical differential X-ray phase-contrast computed tomography. Physica Medica. 2014;30(3):374–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387–95.CrossRefPubMedGoogle Scholar
  14. 14.
    Abbott AM, Dossett LA, Loftus L, Sun W, Fulp W, Sokol GH, et al. Intraoperative radiotherapy for early breast cancer and age: clinical characteristics and outcomes. Am J Surg. 2015;210(4):624–8.CrossRefPubMedGoogle Scholar
  15. 15.
    • Rothschild SI, Thommen DS, Moersig W, Muller P, Zippelius A. Cancer immunology - development of novel anti-cancer therapies. Swiss Med Wkly. 2015;145:w14066 Summarises the mechanism of action and subsequent clinical studies of immune checkpoint antibodies in oncology with a particular focus on melanoma and lung cancer.PubMedGoogle Scholar
  16. 16.
    Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9:28–39.CrossRefPubMedGoogle Scholar
  17. 17.
    Sharma PS, Sharma R, Tyagi T. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Curr Cancer Drug Targets. 2011;11(5):624–53.CrossRefPubMedGoogle Scholar
  18. 18.
    Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007;7(6):475–85.CrossRefPubMedGoogle Scholar
  19. 19.
    Wozel G, Sticherling M, Schon MP. Cutaneous side effects of inhibition of VEGF signal transduction. Journal der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatol : JDDG. 2010;8(4):243–9.CrossRefGoogle Scholar
  20. 20.
    •• Bodnar RJ. Anti-angiogenic drugs: involvement in cutaneous side effects and wound-healing complication. Adv Wound Care. 2014;3(10):635–46 Awareness is needed when treating patients on anti-angiogenic drugs so as not to exacerbate potential wound-healing complications when performing surgical procedures. When performing a surgical procedure, the impact ofadverse effects from the use of anti-angiogenic drugs should be considered to ensure the welfare of the patient. CrossRefGoogle Scholar
  21. 21.
    Chida K, Nakanishi K, Shomura H, Homma S, Hattori A, Kazui K, et al. Spontaneous regression of transverse colon cancer: a case report. Surg Case Reports. 2017;3(1):65.CrossRefGoogle Scholar
  22. 22.
    Challis GB, Stam HJ. The spontaneous regression of cancer: a review of cases from 1900 to 1987. Acta Oncol. 1990;29(5):545–50.CrossRefPubMedGoogle Scholar
  23. 23.
    •• Ascierto PA, Brugarolas J, Buonaguro L, et al. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29–30 November, 2017, Naples, Italy). J Immunother Cancer. 2018;6:69 Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option across several cancer types. With over 3000 immuno-oncology trials ongoing, involving hundreds of research institutes across the globe. The potential use of these different immunotherapeutic options in various combinations with one another and with other treatment modalities is an area of particular promise. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9:325–38.CrossRefPubMedGoogle Scholar
  25. 25.
    Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet. 2009;373(9668):1033–40.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61:35–47.CrossRefPubMedGoogle Scholar
  27. 27.
    Kounis NG, Zavras GM. Histamine-induced coronary artery spasm: the concept of allergic angina. British J Clin Practice. 1991;45(2):121–8.Google Scholar
  28. 28.
    Kounis NG, Soufras GD, Tsigkas G, Hahalis G. Adverse cardiac events to monoclonal antibodies used for cancer therapy: the risk of Kounis syndrome. Oncoimmunology. 2014;3:e27987.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354(9191):1691–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Guglin M, Cutro R, Mishkin JD. Trastuzumab-induced cardiomyopathy. J Card Fail. 2008;14(5):437–44.CrossRefPubMedGoogle Scholar
  31. 31.
    La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy. 2015;35(10):963–76.CrossRefPubMedGoogle Scholar
  32. 32.
    Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–61.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361–75.CrossRefPubMedGoogle Scholar
  34. 34.
    Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–95.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Bilusic M, Madan RA. Therapeutic cancer vaccines: the latest advancement in targeted therapy. Am J Ther. 2012;19(6):e172–81.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Lee HJ, Kim YA, Sim CK, Heo SH, Song IH, Park HS, et al. Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer. Oncotarget. 2017;8(69):113345–59.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    •• Yang L, Yu H, Dong S, Zhong Y, Hu S. Recognizing and managing on toxicities in cancer immunotherapy. Tumor Biol. 2017;39(3):1010428317694542 Treatment toxicity spectrums vary greatly even in same type of cancers. Some side effects are reversible, and can be processed through the standard medicines. However, serious toxicities are lethal, which should be frequently followed-up and identified at an early stage. Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Tayab Andrabi
    • 1
  • Katy E. French
    • 2
  • Muzaffar H. Qazilbash
    • 3
  1. 1.Anesthesiology and PeriOper Med, Margaret and Ben Love Clinic (R6.1365)The University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Anesthesiology and PeriOper Med, Margaret and Ben Love Clinic (R6.1370)The University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Stem Cell Transplantation, John Mendelsohn Faculty Center (FC5.2006)The University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations